Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

ISIS PHARMACEUTICALS, INC. (ISIS)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

ISIS Pharmaceuticals, Inc. : Wall Street Fundamentals Releases New In-Depth Stock Reports on ISIS, KERX, KIOR and MACK

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/15/2013 | 02:45pm CET

Investors are set to receive important information regarding the state of the economy this coming week as reports on inflation and retail sales are to be released and a number of industry bellwethers such as General Electric, Intel, Microsoft and the remaining big banks are also set to report earnings. The Russell 2000 Index closed at a new record high for the third consecutive trading day, the index has gained roughly 22.0 percent year-to-date outpacing both the Dow Jones and the S&P 500. "It's bullish that the Russell 2000 has reversed its downtrend off the May 22 highs and breaking out to new highs," said Craig Johnson, a Piper Jaffray managing director and senior technical research analyst "And when we get an index as broad as the Russell 2000 breaking out to new highs, that suggests that the internals of the market is very strong and we have a lot of stocks that are participating in this move." Here is how some companies in the Russell 2000 Index reacted Friday:

ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) shares traded in the range of $32.29 to $33.94 Friday before settling to close at $33.72, an increase of 3.12 percent. The stock appears to have some support at the $32.06 and $30.46 levels. Shares of ISIS Pharmaceuticals have gained approximately 220.0 percent in 2013.

More information on ISIS Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/ISIS

Keryx Biopharmaceuticals (NASDAQ: KERX) shares traded in the range of $7.93 to $8.15 Friday before settling to close at $8.11, an increase of 1.76 percent. The stock appears to be facing some resistance at the $8.35 and $8.75 levels with some support at $7.69. Shares of Keryx Biopharmaceuticals have gained approximately 210.0 percent in 2013.

More information on Keryx Biopharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/KERX

KiOR Inc. (NASDAQ: KIOR) shares traded in the range of $4.33 to $4.45 Friday before settling to close at $4.37, an increase of 0.23 percent. The stock appears to be facing some resistance at the $4.52 and $4.64 levels with some support at $4.31. Shares of KiOR have fallen approximately 31.8 percent in 2013.

More information on KiOR and access to the free equity report can be found at:
www.WallStreetFundamentals.com/KIOR

Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) shares traded in the range of $4.98 to $5.19 Friday before settling to close at $5.08, an increase of 0.99 percent. The stock appears to be facing some resistance at the $5.32 and $5.65 levels with some support at $5.05. Shares of Merrimack Pharmaceuticals have fallen approximately 16.5 percent in 2013.

More information on Merrimack Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/MACK

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: [email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ISIS PHARMACEUTICALS, INC.
02/22IONIS PHARMACEUTICALS INC : annual earnings release
02/16BIOGEN : and Ionis Pharmaceuticals, Inc. - The New England Journal of Medicine P..
AQ
02/16BIOGEN : and Ionis Pharmaceuticals, Inc. - The New England Journal of Medicine P..
AQ
02/15IONIS PHARMACEUTICALS : to Hold 2017 Financial Results Conference Call
AQ
02/14IONIS PHARMACEUTICALS : The New England Journal of Medicine Publishes SPINRAZA® ..
BU
02/13IONIS PHARMACEUTICALS : to Hold 2017 Financial Results Conference Call
PR
01/30AKCEA THERAPEUTICS : AKCA ON The Move, MNLO Makes A Mark, OBSV Looks Ahead With ..
AQ
01/19IONIS PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
AQ
01/19IONIS PHARMACEUTICALS : ' Inotersen NDA Accepted for Priority Review by the FDA
AQ
01/08AKCEA THERAPEUTICS : Initiates Phase 2b Study of -APOCIII-LRx in Patients with H..
AQ
More news
News from SeekingAlpha
2015Game Plan For The Week - Cramer's Mad Money (12/18/15) 
2015PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr.. 
2015Isis Pharma has had enough, name changed to Ionis Pharmaceuticals 
2015Bear Afoot? No Recession Needed For A Possible Sighting 
2015PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui.. 
Financials ($)
Sales 2017 457 M
EBIT 2017 33,4 M
Net income 2017 -10,3 M
Finance 2017 310 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 112,47
EV / Sales 2017 13,0x
EV / Sales 2018 11,2x
Capitalization 6 222 M
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 14
Average target price 57,5 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
Brett P. Monia Chief Operating Officer
Elizabeth L. Hougen CFO, Principal Accounting Officer & SVP-Finance
B. Lynne Parshall Director
Joseph H. Wender Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, INC.-6.12%6 222
CELLTRION, INC.--.--%34 853
IQVIA HOLDINGS INC2.41%20 749
LONZA GROUP-6.57%19 479
INCYTE CORPORATION-9.71%17 877
NEKTAR THERAPEUTICS39.74%13 613